433 results on '"Giusti, R."'
Search Results
2. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
3. Effects of food-based interventions in the management of chemoradiotherapy-induced nausea and vomiting: a systematic review
4. A Delayed Diagnosis of Cystic Fibrosis in an Adolescent With Chronic Rhinosinusitis With Nasal Polyps
5. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
6. Patients’ Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study
7. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
8. What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations
9. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up
10. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
11. Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment†
12. EP17.06-01 COVID-19 Long-Lasting Effect on Lung Cancer Diagnoses in Italy: Update of the Real-World Multicenter COVID-DELAY Study
13. 592 Evolution of the New York State cystic fibrosis newborn screening algorithm through continued collaboration with accredited cystic fibrosis centers: 20-year experience
14. 601 High normal sweat chloride detected by newborn screening: is there a role for additional genetic testing?
15. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
16. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
17. Inclusivity of the North American Primary Ciliary Dyskinesia (PCD) Foundation Clinical Registry
18. A wireless crackmeters network for the analysis of rock falls at the Pietra di Bismantova natural heritage site (Northern Apennines, Italy)
19. Investigation and characterization of Stellite-based wear-resistant coatings applied to steel moulds by cold-spray
20. 151 Variable genetic counseling access and services for parents of infants who screen positive for cystic fibrosis in New York State
21. 32 Characteristics of 225 infants with cystic fibrosis screen positive, inconclusive diagnosis and cystic fibrosis transmembrane conductance regulator–related metabolic syndrome identified in New York State over a 3-year period
22. Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406](S2059702922000278)(10.1016/j.esmoop.2022.100406)
23. EP06.01-006 Multidisciplinary Team during the COVID-19 Pandemic: The BE-PACIFIC Italian Observational Study Analysis
24. 1124P Pralsetinib in RET fusion-positive non-small cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)
25. 1576P Efficacy of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A network meta-analysis
26. EP05.01-024 Real-life Management of Stage III NSCLC Patients in Italy: The BE-PACIFIC Observational Study
27. 1081P DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients
28. EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
29. 996P Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)
30. Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’
31. DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients
32. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
33. ACCESS TO EARLY PHASE CLINICAL TRIALS AT THE TIME OF THE COVID-19 PANDEMIC: AN ITALIAN SURVEY
34. A wireless crackmeters network for the analysis of rock falls at the Pietra di Bismantova natural heritage site (Northern Apennines, Italy)
35. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
36. 10P Family history of cancer correlates with improved outcome from immunotherapy in NSCLC independent of somatic DNA damage response gene status
37. 80: New York Cystic Fibrosis Newborn Screening Consortium quality improvement: Focus on parent and pediatrician education and development of a statewide standard of care for CF-related metabolic syndrome infants
38. Integration between oncology and palliative care: does one size fit all?
39. Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]
40. Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]
41. 2087P Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
42. 2082P TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
43. Neurological and vascular complications of primary and secondary brain tumours
44. 117P Family history of cancer and improved outcomes with first-line immunotherapy in NSCLC patients
45. Atrial Natriuretic: Factor, B-Endorphin, Parathyroid Hormon and Recombinant Human Erythropoietin in Haemodialysis Patients.
46. Diabetic Nephropathy: Prevalence and Risk Factors
47. Health as a human right, the right to life and the freedom to choose
48. EPS7.03 Variability in evaluation and follow-up of newborns with CFSPID/CRMS In New York State Cystic Fibrosis Specialty Care Centres
49. 79P Statins and immunotherapy: Togetherness makes strength - the potential effect of statins on immunotherapy for NSCLC
50. Tamoxifen and fenretinide in women with metastatic breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.